Company Overview
Allarity Therapeutics, Inc. operates as a clinical-stage precision medicine pharmaceutical company dedicated to developing novel anti-cancer therapeutics designed for patients with unmet medical needs. The firm focuses on the personalized treatment of cancer through the development of drug-specific companion diagnostics, which are essential for matching patients with the appropriate therapeutic agents. This business model places the company within the Healthcare sector and the Biotechnology industry, a classification that defines its reliance on extensive research and development to bring proprietary treatments to market. The company currently maintains a market capitalization of $17.21M and employs a workforce of 6 individuals, reflecting the typical lean operational structure found in early-stage biotechnology firms. These valuation and employment figures indicate that Allarity is a micro-cap entity with limited scale, suggesting that its current financial resources are primarily directed toward advancing its clinical pipeline rather than generating substantial commercial revenue or operating a large-scale manufacturing infrastructure.
Financial Health
The company reports no reported revenue in the trailing twelve months, with a net income of $-15,311,000 and an EBITDA of $-16,967,000, figures that reveal a cost structure heavily dominated by research, development, and clinical trial expenses rather than cost of goods sold. With free cash flow standing at $-10,486,125, the company demonstrates a negative cash burn rate, indicating that it is consuming its cash reserves to fund operations and product development without generating positive cash flow from sales. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard characteristic for clinical-stage biotechnology companies that have not yet achieved commercial product launch or significant sales volume. Despite these negative margins, the company holds $16.89M in cash against $1.39M in debt, resulting in a debt-to-equity ratio of 11.57, which suggests a highly leveraged balance sheet by traditional standards but is common for capital-intensive biotech firms relying on equity financing. The current ratio of 2.33 indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a degree of liquidity buffer despite the cash burn. Furthermore, the return on equity is -122.6% and the return on assets is -51.6%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than profits, a typical phase for companies in the development stage of their product lifecycle.
Valuation Assessment
The trailing twelve-month P/E ratio is 0.12, while the forward P/E is -1.10, a disparity that implies the market expects earnings to remain negative or for the company to continue operating at a loss in the near term. The price-to-book ratio stands at 1.44, indicating that the company's market valuation is 44% higher than the value of its net tangible assets, suggesting a premium assigned to its intellectual property and pipeline potential despite current losses. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to lack of revenue, and an EV/EBITDA of -0.08, suggest that traditional profitability-based valuation models are not applicable, and the stock is being valued primarily on its clinical assets and potential future commercialization. The stock has traded between a 52-week high of $2.35 and a 52-week low of $0.61, meaning the current price sits at a specific point within this range that reflects recent market sentiment and volatility. The beta value is 0.20, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting that investor demand for the asset is currently less sensitive to general market fluctuations than typical equities.
Growth & Income
The company reports N/A for revenue growth year-over-year and N/A for earnings growth year-over-year, reflecting that the metrics are not applicable to a company with no commercial revenue or consistent earnings history. As a non-dividend payer, the company does not distribute any cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically reinvested into growth initiatives such as clinical trials rather than distributed as income. Since the company has not generated positive earnings, the concept of a sustainable payout ratio is not applicable, and the firm's strategy relies entirely on external capital to fund its operations and research goals. Overall, the growth and income profile for Allarity Therapeutics, Inc. is characterized by zero current revenue growth, zero dividend income, and a reliance on capital markets to sustain its clinical-stage operations until product commercialization occurs.